PExA (PEXA) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 were SEK 0, down from SEK 168,268 in Q1 2024, reflecting a strategic focus on development and positioning for future growth rather than reduced demand.

• Net loss after financial items was SEK -2,248,575, compared to SEK -1,948,643 in the same quarter last year.

• Cash and cash equivalents at period end were SEK 3,867,797, down from SEK 8,352,917 a year earlier.

• PEXA's technology continues to gain validation through new studies, patent milestones, and international collaborations, supporting its transition from research to clinical applications.

Financial highlights

• Net sales: SEK 0 (Q1 2024: SEK 168,268).

• Net loss after financial items: SEK -2,248,575 (Q1 2024: SEK -1,948,643).

• Earnings per share: SEK -0.04 (Q1 2024: SEK -0.05).

• Equity ratio: 77.6% (Q1 2024: 88.6%).

• Cash flow from operating activities: SEK -1,725,636 (Q1 2024: SEK -1,119,979).

Outlook and guidance

• Management is focusing resources on three strategic areas: early diagnosis and risk assessment of airway diseases, local drug evaluation and pharmacokinetics in the lung, and a comprehensive solution for sample collection, analysis, and data presentation.

• Ongoing clinical studies in lung embolism, lung cancer, and COPD are expected to yield important results during the year.

• The board assesses that available funds are insufficient to finance the next 12 months' operations and is exploring options for additional capital.